📈 Economy · Tomorrow

AstraZeneca PLC (LON: AZN; NASDAQ: AZN) beats analyst Core EPS consensus of approx. USD 4.80 per ADS for H1 2026 (29 July 2026, before market open) and confirms full-year guidance (confirmed by AstraZeneca press release)

Pending ✦ AI-generated prediction Published on 26. July 2026 · Predicted for 29. July 2026 · Based on: Statistical Pattern

Probability

68%

AstraZeneca has consistently beaten consensus expectations over the past six semi-annual and quarterly results, driven by oncology blockbusters (Tagrisso, Enhertu, Imfinzi) and the rare disease portfolio (Ultomiris, Soliris). FY2026 Core EPS growth of ≥10% YoY is company guidance. H1 2026 boosted by Farxiga launches in new indications and emerging market growth. No direct Polymarket data; historical beat probability >70% for AZ. Risks: FX pressure USD/GBP, generic competition for Tagrisso.

Data basis for this prediction

AstraZeneca IR: FY2025 Full Year Results – Core EPS Wachstumspfad, Guidance FY2026, Februar 2026
Reuters: AstraZeneca H1 2026 Earnings Preview – Oncology pipeline momentum, Juli 2026
Yahoo Finance: AZN Earnings History 2024–2026 – Konsekutive Beats, Stand Juli 2026
Macrotrends: AstraZeneca Core EPS Quarterly History 2023–2026

Note: This is an AI-generated statistical forecast for entertainment and information purposes. It does not constitute investment advice or a recommendation to buy or sell any financial instrument.

Verdict: Pending

This prediction is still open. It will be evaluated automatically against real-world sources after its due date.

Related Predictions

📈 Economy ✦ AI

Palantir Technologies Inc. (NASDAQ: PLTR) beats adjusted Non-GAAP EPS consensus of approx. USD 0.34 per share in Q2-2026 earnings (3 August 2026, after market close, confirmed by Palantir press release)

Palantir has beaten the Non-GAAP EPS consensus for eight consecutive quarters. Q2 2026 consensus stands at ~USD 0.34 per share (vs. USD 0.16 in Q2 2025, +113% YoY), driven by US government contracts (Army AIP, SAS expansion) and strongly growing US commercial segment (AIP Enterprise deployments). Note: the separate long-term platform prediction (stock decline >45% by year-end) relates to valuation, not short-term earnings performance – no contradiction. Tipranks/Polymarket historical beat track for PLTR: >85%.

75%

Next Month · Predicted for 3. Aug 2026

📈 Economy ✦ AI

Microsoft Corporation (NASDAQ: MSFT) beats adjusted Non-GAAP EPS consensus of approx. USD 4.21 in Q4-FY2026 earnings (29 July 2026, after market close, confirmed by Microsoft press release)

Analyst consensus for Microsoft's Q4 FY2026 stands at USD 4.21–4.24 Non-GAAP EPS (+15.3% YoY). Microsoft has beaten estimates in four consecutive quarters. Azure growth expected above 33% (separate platform prediction), with Copilot Enterprise and GitHub subscriptions adding upside. No direct Polymarket data; historical beat track and sector momentum (Intel Q2 2026 beat by 100%, Amazon expectations also elevated) imply >80% hit probability.

82%

Tomorrow · Predicted for 29. Jul 2026

📈 Economy ✦ AI

Eurostat Flash CPI Eurozone July 2026 (release approx. 31 July 2026): Annual inflation rate at or above 2.3% (confirmed by Eurostat press release)

The ECB plans a rate hike to 2.50% in September 2026 (separate platform prediction), indicating persistent inflation above the 2.0% target. Brent crude currently at ~USD 97/bbl (+34% since early July 2026 due to Middle East tensions), acting as energy price driver for the July CPI. EUR/USD at 1.1367 (24 July 2026) – moderate imported inflation. No direct Polymarket data; author estimate: 65% for annual rate ≥2.3%. Risk: base effects could accelerate disinflation.

65%

Next Week · Predicted for 31. Jul 2026